Valiant Laboratories Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Valiant Laboratories Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹140
Per ShareLot Size
105 Shares
Minimum Investment
₹14,700
Issue Size
₹152.46 Cr
Face Value
₹10
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Valiant Laboratories Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
82.52%
Promoter Holding (Post-Issue)
61.84%
Issue Type
Book Building
ISIN
INE0JWS01017
About the Company
Valiant Laboratories Limited is an Active Pharmaceutical Ingredient ("API") / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. Bulk drugs/Active Pharmaceutical Ingredients (API) serve as raw materials for manufacturing finished dosage forms or formulations. Paracetamol (Scientific name: Acetaminophen or para-hydroxyacetanilide - C8H9NO2), is one of the most commonly taken analgesic worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. We manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of our customers.
Industry Overview
The Company operates in the pharmaceutical API industry. The pharmaceutical API industry in India is ranked third-largest globally in terms of volume. The paracetamol API industry (Domestic consumption+ exports) grew from Rs. 22 billion in fiscal 2017 to Rs. 39 billion in fiscal 2023. Going forward the paracetamol API industry is expected to clock a CAGR of 5-7% between fiscal 2023 and fiscal 2027, largely driven by the demand from domestic formulation manufacturers as well as export markets.
Company History
Valiant Laboratories Limited was originally formed as a partnership firm under the name and style of `M/s. Bharat Chemicals' pursuant to the deed of partnership dated October 17, 1980, amended and restated from time to time. Subsequently, the partnership firm, M/s. Bharat Chemicals was converted into a public limited company under the provisions of the Companies Act with the name "Valiant Laboratories Limited" pursuant to certificate of incorporation dated August 16, 2021 issued by the by Central Registration Centre, Registrar of Companies.
Products & Services
- The Company is an Active Pharmaceutical Ingredient ("API") / Bulk Drug manufacturing company
Growth Strategy
- Diversification into new chemistries and industry.
- Increase in market share.
- Improve operational efficiencies through backward integration of Proposed Facility:
- Increase its penetration into international markets including regulated markets.
Customer Base
Wholesalers and Retailers
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY23 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offer of up to 10,890,000 equity shares of face value of Rs. 10 each ("Equity Shares") of Valiant Laboratories Limited ("Company" or "Issuer") for cash at a price of Rs. 140 per equity share (including a share premium of Rs. 130 per equity share) ("Issue Price") aggregating up to Rs. 152.46 crores ("Issue"). The issue shall constitutes 25.06% of the fully-diluted post- issue paid-up equity share capital of the company. The face value of equity shares is Rs. 10 each. The issue price is 14 times the face value of the equity shares.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Experienced promoter and strong management team:
- Strong Focus on Sustainability in Operations:
- Strategically located manufacturing facility:
- Quality-Focused Compliant Manufacturing and R&D Infrastructure:
- Reducing dependence on import of raw materials:
- The company is subject to strict quality requirements, regular inspections and audits by its customers and any failure to comply with quality standards may lead to cancellation of existing and future orders and could negatively impact the company business, financial condition, results of operations and prospects it may impact the reputation as well.
- The company does not have long-term agreements with its suppliers for raw materials and an inability to procure the desired quality, quantity of its raw materials in a timely manner and at reasonable costs, or at all, may have a negative impact on the business, results of operations, financial condition and cash flows.
- If there are delays in setting up the Proposed Facility or if the costs of setting up and the possible time or cost overruns related to the Proposed Facility or the purchase of plant and machinery for the Proposed Facility are higher than expected, it could have a material adverse effect on its financial condition, results of operations and growth prospects.
- The company's single product manufacturing company and any changes to the paracetamol API industry or the company product demand will adversely affect its revenues, financials and profitability.
- The majority of its operative income is derived from the domestic market and any adverse developments in this market could adversely affect its business.